ImmuPharma PLC (UK) Today
| IMM Stock | 1.57 0.02 1.26% |
Performance5 of 100
| Odds Of DistressLess than 9
|
ImmuPharma PLC is trading at 1.57 as of the 25th of November 2024, a 1.26 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.54. ImmuPharma PLC has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for ImmuPharma PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
ImmuPharma PLC is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 416.44 M outstanding shares. More on ImmuPharma PLC
Moving against ImmuPharma Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ImmuPharma Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ImmuPharma PLC's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ImmuPharma PLC or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman CEO | XIV FCCA | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
ImmuPharma PLC's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ImmuPharma PLC's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsImmuPharma PLC can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ImmuPharma PLC's financial leverage. It provides some insight into what part of ImmuPharma PLC's total assets is financed by creditors.
| |||||
ImmuPharma PLC (IMM) is traded on London Exchange in UK and employs 5 people. ImmuPharma PLC is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ImmuPharma PLC's market, we take the total number of its shares issued and multiply it by ImmuPharma PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ImmuPharma PLC operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 416.44 M outstanding shares.
ImmuPharma PLC generates negative cash flow from operations
Check ImmuPharma PLC Probability Of Bankruptcy
Ownership AllocationImmuPharma PLC has a total of 416.44 Million outstanding shares. ImmuPharma PLC secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ImmuPharma Ownership Details
ImmuPharma PLC Risk Profiles
Although ImmuPharma PLC's alpha and beta are two of the key measurements used to evaluate ImmuPharma PLC's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.9 | |||
| Semi Deviation | 3.17 | |||
| Standard Deviation | 2.87 | |||
| Variance | 8.24 |
ImmuPharma Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in ImmuPharma PLC without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
ImmuPharma PLC Corporate Management
Elected by the shareholders, the ImmuPharma PLC's board of directors comprises two types of representatives: ImmuPharma PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmuPharma. The board's role is to monitor ImmuPharma PLC's management team and ensure that shareholders' interests are well served. ImmuPharma PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmuPharma PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laura MauranAmbrosino | Chief Biotech | Profile | |
| Sbastien Goudreau | Chief Biotec | Profile | |
| MD PharmD | Head Development | Profile | |
| Lara SuchestonCampbell | Head Affairs | Profile |
Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.